Forma Therapeutics Holdings Inc. (FMTX) News
Filter FMTX News Items
FMTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
FMTX News Highlights
- For FMTX, its 30 day story count is now at 2.
- Over the past 23 days, the trend for FMTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GILD, MD and PSA are the most mentioned tickers in articles about FMTX.
Latest FMTX News From Around the Web
Below are the latest news stories about FORMA THERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate FMTX as an investment opportunity.
Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the DiseaseHANOVER, MD and WATERTOWN, Mass., September 30, 2022--Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease |
Biotech Stock Roundup: GILD's Updates, FMTX Up on NVO Deal, SPRO Surges & MoreRegulatory and acquisition updates from Gilead (GILD) and Forma (FMTX) are key highlights from the biotech sector during the past week. |
Novo Nordisk (NVO) to Tap Into SCD Space With Forma AcquisitionNovo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space. |
Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition NewsThere's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news. |
Guardforce AI (GFAI) Stock Gets a Boost From New Exec TeamGuardforce AI (GFAI) stock is climbing higher on Thursday after announcing a new executive team that will lead the company. |
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics BuyoutNovo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. |
Why Forma Therapeutics Holdings Stock Is On Fire TodayShares of Forma Therapeutics Holdings (NASDAQ: FMTX) were up by a healthy 49% as of 1:17 p.m. ET Thursday afternoon. The small-cap biotech's stock is roaring higher in response to a $1.1 billion buyout agreement with Danish drugmaker Novo Nordisk (NYSE: NVO). Novo Nordisk has agreed to pay $20 a share for Forma Therapeutics in cash. |
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics DealNovo Nordisk A/S (NYSE: NVO) has agreed to acquire Forma Therapeutics Holdings Inc (NASDAQ: FMTX) for $20 per share in cash, representing a total equity value of $1.1 billion. The deal value offers a premium of 92% to Forma Therapeutics' volume-weighted average price per share over the past 30 days. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on treating sickle cell disease (SCD) and rare blood disorders. The acquisition of Forma Therapeutics, including its lead deve |
UPDATE 1-Novo Nordisk to acquire Forma Therapeutics in $1.1. bln dealDanish drugmaker Novo Nordisk has agreed to buy Forma Therapeutics in a deal valued at $1.1 billion to expand its blood disorders portfolio, the companies said on Thursday. "We have an ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease," Novo Nordisk said in a statement. Novo Nordisk, best known for its diabetes drugs, said it would pay 20 dollar per share, which is a premium of 92% to the U.S. company's volume-weighted average price per share over the past 30 days. |
Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billionForma Therapeutics Holdings Inc. announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m. Eastern, while the U.S.-listed share of Novo Nordisk were little changed. Under terms of the deal, Forma shareholders will received $20 in cash for each Forma share they own, which represents a 49.3% premium to Wednesday's closing price of $13.40, and implies a market capitalization of $957. |